Automated interviews to validate distress measures in cancer survivors

自动访谈以验证癌症幸存者的痛苦措施

基本信息

  • 批准号:
    8446988
  • 负责人:
  • 金额:
    $ 21.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-01 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): In addition to physical health effects, cancer survivors are known to be at increased risk for a variety of long- term psychosocial effects, most commonly depression and anxiety.3, 7-12 Young adult (YA) survivors are a particularly vulnerable group, as cancer disrupts their physical and emotional development, and they will live with late-effects for many years after treatment.12, 15-18 Studies of YA survivors show high rates of psychological distress,10, 19 as well as many barriers to receiving appropriate psychosocial care.12, 20, 21 Research to understand the etiology of these psychological late-effects and to identify and treat affected survivors has benefited from the use of self-report symptom checklists developed for psychiatric populations,12-14 but almost no research has been done to validate these measures in cancer survivors. In fact, reviews of YA survivor care consistently note that both research and patient care are hampered by a lack of patient reported outcome (PRO) measures that have been validated for this population.15, 20, 21 To address this critical need, this study investigates validity of existing measures of anxiety and depression by comparing them to a validated psychiatric assessment in a sample of 200 YA cancer survivors (age 18-40). Using the Structured Clinical Interview for DSM Disorders (SCID) 22 as a "gold standard," the validity of the Brief Symptom Inventory-18 (BSI- 18), 23 and PROMIS initiative 24, 25 anxiety and depression short forms will be assessed. Previous research supports reliability of the BSI-18 and PROMIS measures, 13, 24, and 25, 27 but no studies have validated them against a psychiatric diagnostic criterion. In addition to checklist measures, validity and utility of an innovative diagnostic interview, the Primary Care Evaluation of Mental Disorders (PRIME-MD), administered using computerized automated telephone interview (ATI) will also be investigated. Studies have validated both in-person and ATI versions of PRIME-MD in psychiatric and medical patients, 28-31 but this will be the first to study its utility in cance survivors. Analysis will focus on identifying case-rules for study measures to optimize identification of survivors with clinically significant depression and anxiety on the SCID. The study will also assess whether survivors are more comfortable disclosing sensitive information regarding sexual and suicidal symptoms using ATI compared to written forms, with the goal of determining if ATI enhances reporting of these important but often neglected symptoms. By examining the criterion validity of these measures, and identifying best methods for using them to detect survivors with clinically significant psychological symptoms, this study will greatly enhance the value of these measures and provide new approaches for research and clinical care of YA survivors. Although this research takes place in the context of YA cancer survivorship, results will be informative for developing best practices for enhancing PRO measures of psychological distress and sensitive behaviors in other populations.
描述(由申请人提供):除了身体健康的影响外,癌症幸存者的风险增加了多种长期的心理社会影响的风险,最常见的是抑郁症和焦虑。3,7-12岁的年轻成人(YA)幸存者特别脆弱,癌症特别脆弱,因为癌症会破坏他们的身体和情绪发展,并且在治疗后效应后期有很多年后期的效果。 19以及接受适当的社会心理护理的许多障碍。12、20、21研究以了解这些心理后期效应的病因并识别和治疗受影响的幸存者的病因,从使用为精神病学人群开发的自我报告症状清单的使用中受益于12-14的自我报告症状清单,但几乎没有进行研究以验证这些癌症幸存者的措施。实际上,对YA幸存者护理的评论一致地注意到,研究和患者护理受到病人报告的结果(PRO)措施的障碍。15、20、21为了满足这一关键需求,这项研究调查了现有的焦虑和抑郁症度量的有效性 通过将它们与200个YA癌症幸存者样本中的精神病评估进行比较(18-40岁)。将DSM疾病的结构化临床访谈(SCID)22用作“黄金标准”,将评估简短症状库存18(BSI-18),23和Promis Initiative 24、25焦虑和抑郁症状的有效性。先前的研究支持BSI-18和Promis措施的可靠性,即13、24和25、27,但没有研究对他们针对精神病诊断标准进行了验证。除了清单措施,创新诊断访谈的有效性和实用性外,还将研究使用计算机化自动电话访谈(ATI)进行精神疾病(PRIME-MD)的初级保健评估(PRIME-MD)。研究已经验证了精神病和医学患者中Prime-MD的面对面和ATI版本,28-31,但这将是第一个研究其在Cance幸存者中的效用。分析将着重于确定研究措施的病例规则,以优化对SCID的临床明显抑郁和焦虑的幸存者的识别。该研究还将评估幸存者是否更舒适地披露使用ATI的敏感信息与书面形式相比,目的是确定ATI是否增强了报告这些重要但经常被忽略的症状的报告。通过检查这些措施的标准有效性,并确定使用它们来检测具有临床心理症状的幸存者的最佳方法,这项研究将大大提高这些措施的价值,并为YA幸存者的研究和临床护理提供新的方法。尽管这项研究是在YA癌症幸存者的背景下进行的,但结果将为发展其他人群的心理困扰和敏感行为的最佳实践提供信息。

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Evaluating sensitive symptoms in young adult cancer survivors: acceptability of suicidal ideation and sexual health items across administration modes.
评估年轻成年癌症幸存者的敏感症状:跨管理模式自杀意念和性健康项目的可接受性。
  • DOI:
    10.1007/s11764-022-01237-5
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Chevalier,LydiaL;Blackmon,JaimeE;Bober,SharonL;Roman,Anthony;Chang,Grace;Recklitis,ChristopherJ
  • 通讯作者:
    Recklitis,ChristopherJ
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christopher John Recklitis其他文献

Christopher John Recklitis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Christopher John Recklitis', 18)}}的其他基金

STEP-YA: An Online Self-Management Intervention for Young Adult Cancer Survivors with Insomnia
STEP-YA:针对失眠的年轻成年癌症幸存者的在线自我管理干预措施
  • 批准号:
    10458886
  • 财政年份:
    2022
  • 资助金额:
    $ 21.39万
  • 项目类别:
STEP-YA: An Online Self-Management Intervention for Young Adult Cancer Survivors with Insomnia
STEP-YA:针对失眠的年轻成年癌症幸存者的在线自我管理干预措施
  • 批准号:
    10630334
  • 财政年份:
    2022
  • 资助金额:
    $ 21.39万
  • 项目类别:
Sleep Treatment Education Program-1 (STEP-1): A Randomized Trial of a Self-Management Insomnia Intervention for Cancer Survivors
睡眠治疗教育计划-1 (STEP-1):癌症幸存者自我管理失眠干预的随机试验
  • 批准号:
    10524472
  • 财政年份:
    2022
  • 资助金额:
    $ 21.39万
  • 项目类别:
Sleep Treatment Education Program-1 (STEP-1): A Randomized Trial of a Self-Management Insomnia Intervention for Cancer Survivors
睡眠治疗教育计划-1 (STEP-1):癌症幸存者自我管理失眠干预的随机试验
  • 批准号:
    10656572
  • 财政年份:
    2022
  • 资助金额:
    $ 21.39万
  • 项目类别:
CBTI-CS: A Novel Cognitive-Behavioral Treatment for Insomnia in Cancer Survivors
CBTI-CS:一种治疗癌症幸存者失眠的新型认知行为疗法
  • 批准号:
    9190366
  • 财政年份:
    2016
  • 资助金额:
    $ 21.39万
  • 项目类别:
Automated interviews to validate distress measures in cancer survivors
自动访谈以验证癌症幸存者的痛苦措施
  • 批准号:
    8301158
  • 财政年份:
    2012
  • 资助金额:
    $ 21.39万
  • 项目类别:
Enhanced Self-Appraisal After Cancer: A Bias in Survivors' Self-Report?
癌症后自我评价增强:幸存者自我报告存在偏见?
  • 批准号:
    8038230
  • 财政年份:
    2010
  • 资助金额:
    $ 21.39万
  • 项目类别:
Enhanced Self-Appraisal After Cancer: A Bias in Survivors' Self-Report?
癌症后自我评价增强:幸存者自我报告存在偏见?
  • 批准号:
    7752638
  • 财政年份:
    2009
  • 资助金额:
    $ 21.39万
  • 项目类别:
Enhanced Self-Appraisal After Cancer: A Bias in Survivors' Self-Report?
癌症后自我评价增强:幸存者自我报告存在偏见?
  • 批准号:
    7877031
  • 财政年份:
    2009
  • 资助金额:
    $ 21.39万
  • 项目类别:

相似国自然基金

时空序列驱动的神经形态视觉目标识别算法研究
  • 批准号:
    61906126
  • 批准年份:
    2019
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
  • 批准号:
    41901325
  • 批准年份:
    2019
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
  • 批准号:
    61802133
  • 批准年份:
    2018
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
  • 批准号:
    61872252
  • 批准年份:
    2018
  • 资助金额:
    64.0 万元
  • 项目类别:
    面上项目
针对内存攻击对象的内存安全防御技术研究
  • 批准号:
    61802432
  • 批准年份:
    2018
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Cognitive Health and Modifiable Factors of Daily Sleep and Activities Among Dementia Family Caregivers
痴呆症家庭护理人员的认知健康状况以及日常睡眠和活动的可改变因素
  • 批准号:
    10643624
  • 财政年份:
    2023
  • 资助金额:
    $ 21.39万
  • 项目类别:
Pilot Studies of PAX3-FOXO1 Fusions Proteins in Alveolar Rhabdomyosarcoma
PAX3-FOXO1 融合蛋白在肺泡横纹肌肉瘤中的初步研究
  • 批准号:
    10726763
  • 财政年份:
    2023
  • 资助金额:
    $ 21.39万
  • 项目类别:
Targeting HNF4-induced thrombo-inflammation in Chagas disease
针对恰加斯病中 HNF4 诱导的血栓炎症
  • 批准号:
    10727268
  • 财政年份:
    2023
  • 资助金额:
    $ 21.39万
  • 项目类别:
Impact of benzene-induced MIA on fetal T cell development
苯诱导的 MIA 对胎儿 T 细胞发育的影响
  • 批准号:
    10605881
  • 财政年份:
    2023
  • 资助金额:
    $ 21.39万
  • 项目类别:
Validation of the joint-homing and drug delivery attributes of novel peptides in a mouse arthritis model
在小鼠关节炎模型中验证新型肽的关节归巢和药物递送特性
  • 批准号:
    10589192
  • 财政年份:
    2023
  • 资助金额:
    $ 21.39万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了